Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (171-180 of 198) with videos related to

Pageof 20
Sort By:
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.
Clinical Lung Cancer|June 25, 2017
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE StudySara Pilotto, Antonio Rossi, Tiziana Vavalà, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trialsAlessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trialEnrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialCesare Gridelli, Fortunato Ciardiello, Ciro Gallo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancerMassimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patientsMaria Lucia Iacovino, Laura Arenare, Alessandro Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 TrialMaria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
Pageof 20

Showing results (171-180 of 198) with videos related to

Sort By:
Pageof 20
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.
Clinical Lung Cancer|June 25, 2017
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE StudySara Pilotto, Antonio Rossi, Tiziana Vavalà, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2018
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Alessandro Morabito, Luigi Cavanna, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trialsAlessandro Morabito, Maria Carmela Piccirillo, Paolo Maione, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trialEnrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trialCesare Gridelli, Fortunato Ciardiello, Ciro Gallo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2012
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancerMassimo Di Maio, Natasha B Leighl, Ciro Gallo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patientsMaria Lucia Iacovino, Laura Arenare, Alessandro Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trialSandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 TrialMaria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, et al.
Pageof 20